SRX3207 | CAS 2254693-15-5

SRX3207

This product is for research use only, not for human use. We do not sell to patients.

For small sizes, please check our retail website as below: www.invivochem.com

Size	Price	Stock
250mg	$1950	Check With Us
500mg	$3250	Check With Us
1g	$4875	Check With Us

: [email protected] [email protected]

Cat #: V2390 CAS #: 2254693-15-5 Purity ≥ 99%

Description: SRX-3207 (SRX3207) is a novel, potent, orally bioactive and dual inhibitor of Syk-PI3K with anti-tumor activity. As a first-in-class' dual Syk/PI3K inhibitor, SRX3207 was designed for the combinatorial inhibition of Syk and PI3K in one small molecule. This chemotype demonstrates efficacy in multiple tumor models and represents a novel combinatorial approach to activate antitumor immunity.

References: [1]. Shweta Joshi, et al. Macrophage Syk–PI3Kγ Inhibits Antitumor Immunity: SRX3207, a Novel Dual Syk–PI3K Inhibitory Chemotype Relieves Tumor Immunosuppression. Molecular Cancer Therapeutics. 2020.

Top Publications Citing Invivochem Products

Product Catalog 2022

Guide to Product Handling

Publications Citing InvivoChem Products

Product Promise

Physicochemical and Storage Information
Protocol
Related Biological Data
Stock Solution Preparation
Quality Control Documentation

Molecular Weight (MW)	555.657
Molecular Formula	C29H29N7O3S
CAS No.	2254693-15-5
SMILES Code	O=C1C2=C(C(C3=CC=C(NC4=NC=CC(N5N=C(C)C(CN6CCC6)=C5)=N4)C=C3)=CS2)OC(N7CCOCC7)=C1
Synonyms	SRX3207; SRX-3207; SRX 3207;

Protocol	In Vitro	SRX3207 (10 μmol/L) is able to block p-AKT at concentration. SRX3207 has sufficient solubility in water (43 μmol/L).
	In Vivo	SRX3207 (10 mg/kg, orally) increases antitumor immune response. Animal Model: LLC or B16 or B16-OVA or CT26 (1 × 105) cells were injected subcutaneously into syngeneic mice. Dosage: 10 mg/kg. Administration: Orally, starting from day 10 when tumors reached 100 mm3 until tumors were harvested on day 21. Result: Blocked phosphorylation of Syk at 348 site and Y525/526 site. Blocked immunosuppressive MΦ polarization. Blocked tumor growth and increased survival effectively.
	Animal model	LLC or B16 or B16-OVA or CT26 (1 × 105) cells were injected subcutaneously into syngeneic mice.
	Dosages	10 mg/kg.
	Administration	Orally, starting from day 10 when tumors reached 100 mm3 until tumors were harvested on day 21.

These protocols are for reference only. InvivoChem does not independently validate these methods.

Preparing Stock Solutions

Solvent volume to be added	Mass (the weight of a compound)
Mother liquor concentration	1mg	5mg	10mg	20mg
1mM	1.7997 mL	8.9984 mL	17.9967 mL	35.9934 mL
5mM	0.3599 mL	1.7997 mL	3.5993 mL	7.1987 mL
10mM	0.1800 mL	0.8998 mL	1.7997 mL	3.5993 mL
20mM	0.0900 mL	0.4499 mL	0.8998 mL	1.7997 mL

The molarity calculator equation

Mass(g) = Concentration(mol/L) × Volume(L) × Molecular Weight(g/mol)

Mass

Concentration

Volume

Molecular Weight*

The dilution calculator equation

Concentration_(start) × Volume_(start) = Concentration_(final) × Volume_(final)

This equation is commonly abbreviated as: C₁ V₁ = C₂ V₂

Concentration_(start)

Volume_(start)

Concentration_(final)

Volume_(final)

Step One: Enter information below

Dosage mg/kg Average weight of animals g Dosing volume per animal µL Number of animals

Step Two: Enter the in vivo formulation

%DMSO + % + %Tween 80 + %ddH₂O

Calculation Results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in µL DMSO(Master liquid concentration mg/mL) ,Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.

Method for preparing in vivo formulation: Take µL DMSO master liquid, next add µL PEG300, mix and clarify, next add µL Tween 80,mix and clarify, next add µL ddH₂O,mix and clarify.

Note:

(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.